GBA Gene Therapy for Parkinson's Disease

📖 Wiki Page

therapeutic1237 wordssynced 2026-04-02

GBA Gene Therapy for Parkinson's Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">GBA Gene Therapy for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Migalastat (Galafold)</td>
<td>Amicus</td>
</tr>
<tr>
<td class="label">Ambroxol</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Venglustat (GZ161)</td>
<td>Sanofi</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">ambroxol-PD</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">GBA-PD Natural History</td>
<td>Observational</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">AADC</td>
<td>Enzyme replacement</td>
</tr>
<tr>
<td class="label">GBA</td>
<td>Gene therapy/chaperone</td>
</tr>
<tr>
<td class="label">LRRK2</td>
<td>Kinase inhibitor</td>
</tr>
<tr>
<td class="label">SNCA</td>
<td>ASO/siRNA</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Status</td>
</tr>
<tr>
<td class="label">IGF1 Peptide</td>
<td>Research</td>
</tr>
<tr>
<td class="label">IGF1 Mimetics</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Gene Therapy</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Receptor Agonists</td>
<td>Research</td>
</tr>
</table>

Introduction

Overview

...

GBA Gene Therapy for Parkinson's Disease

Introduction

Overview

GBA Gene Therapy is an emerging experimental approach for treating Parkinson's disease (PD) in patients with GBA mutations. The glucocerebrosidase (GCase) enzyme, encoded by the GBA gene, plays a critical role in lysosomal function, and mutations in GBA represent one of the most significant genetic risk factors for PD. [@sardi2011]

Background

GBA Mutations and Parkinson's Disease

10-15% of PD patients carry GBA mutations
GBA mutations increase PD risk 5-6 fold in heterozygotes
Associated with earlier onset and more severe cognitive symptoms
GBA is the most common genetic risk factor for PD aside from LRRK2 and SNCA

The GCase-Lysosome Connection

The glucocerebrosidase enzyme (GCase) is responsible for breaking down glucosylcer lysamide inosomes. Loss of GCase function leads to: [@mazzulli2016]

Glucosylceramide accumulation in lysosomes

Lysosomal dysfunction and impaired [autophagy](/entities/autophagy)

[α-Synuclein](/proteins/alpha-synuclein) aggregation (GCase regulates SNCA clearance)

Mitochondrial dysfunction

Endoplasmic reticulum stress

Therapeutic Approaches

1. Enzyme Replacement Therapy (ERT)

Recombinant GCase delivery to increase enzymatic activity
Limitations: Cannot cross the blood-brain barrier
Currently only approved for Gaucher disease, not PD

2. Gene Therapy Vectors

AAV Vectors

AAV9 serotype preferentially targets [neurons](/entities/neurons)
Delivers functional GBA1 gene
Promoters: Synapsin (neuronal), [GFAP](/entities/gfap) (astrocytic)
Clinical trials in planning stages

Lentiviral Vectors

Used in preclinical studies
Provides long-term expression
Safety concerns about insertional mutagenesis

3. Small Molecule Chaperones

Pharmacological chaperones stabilize mutant GCase and promote proper folding: [@mullin2020]

4. Substrate Reduction Therapy

Venglustat (GZ/SAR402671) reduces glucosylceramide substrate
Aims to compensate for reduced GCase activity
Clinical trials for PD with GBA mutations

5. Gene Editing (CRISPR/Cas9)

In vivo gene editing approaches being developed
Corrects GBA mutations in the brain
Challenges: Delivery across blood-brain barrier
Preclinical stages

Clinical Development

Ongoing Trials

Challenges

[Blood-brain barrier](/entities/blood-brain-barrier) - vectors must cross BBB

Delivery - targeting specific brain regions (substantia nigra)

Expression levels - balancing therapeutic vs. toxic overexpression

Immunogenicity - immune response to viral vectors

Patient selection - identifying GBA mutation carriers

Mechanism of Action

In Parkinson's Disease

Restore GCase activity in neurons and glia

Reduce glucosylceramide accumulation

Improve lysosomal function

Enhance α-synuclein clearance

Protect dopaminergic neurons

Downstream Effects

Preclinical Evidence

Animal Models

Gba1 knockout mice: Show increased α-synuclein aggregation
AAV-GBA delivery: Reduces α-synuclein in mouse models
Combination therapy: GBA + SNCA knockdown shows synergy

Cell Models

iPSC-derived neurons from GBA PD patients
Gene therapy rescues lysosomal deficits
Reduces pathological α-synuclein

Comparison to Other PD Gene Therapies

Future Directions

Promising Strategies

Brain-targeted AAV vectors - improved BBB crossing

Regulatable promoters - control expression levels

Combination approaches - GBA + α-synuclein targeting

Patient stratification - GBA mutation carriers only

Early intervention - prodromal PD patients

Key Questions

Will gene therapy work in sporadic PD?
What is the optimal delivery method?
How long will therapeutic effects last?
Can this prevent cognitive decline in GBA-PD?

Key Publications

[Glucocerebrosidase and Parkinson's disease](https://pubmed.ncbi.nlm.nih.gov/25977245) - Reviews GBA-PD connection

[AAV-GBA gene therapy for PD](https://pubmed.ncbi.nlm.nih.gov/29867231) - Preclinical proof of concept

[Ambroxol for PD trial](https://pubmed.ncbi.nlm.nih.gov/33185066) - Phase II trial design

[Substrate reduction therapy in PD](https://pubmed.ncbi.nlm.nih.gov/28750070) - Venglustat development

See also: [Gene Therapy](treatments/gene-therapy), [AAV Vectors](treatments/aav-vectors-neurodegenerative-gene-therapy), [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

[ClinicalTrials.gov: GBA Gene Therapy](https://clinicaltrials.gov/search?cond=Parkinson+Disease&intr=GBA+gene+therapy)
[NIH: GBA1 and Parkinson Disease](https://www.ninds.nih.gov/current-research/focus-areas/parkinsons-disease)
[Michael J. Fox Foundation: GBA](https://www.michaeljfox.org/gba-parkinsons-research)

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

2.彭斯等. (2018). "AAV-GBA1 gene delivery in mouse models." Mol Ther 26(8):2052-2065. PMID: 29982369(https://pubmed.ncbi.nlm.nih.gov/29982369/).

[@ref2019]:

[@mazzulli]: Mazzulli JR, et al. "Small molecule GBA activators." Cell 166(6):1534-1545. PMID: 27594434(https://pubmed.ncbi.nlm.nih.gov/27594434/).

[@schondorf]: Schondorf DC, et al. "iPSC models of GBA1-associated Parkinson's disease." Nat Commun 9(1):2904. PMID: 30013145(https://pubmed.ncbi.nlm.nih.gov/30013145/).

IGF1 in Neurodegeneration

Alzheimer's Disease

IGF1 signaling plays a complex role in AD pathophysiology
Both beneficial (neuroprotection) and detrimental (Aβ production) effects
Brain IGF1 resistance observed in AD patients
Therapeutic potential of IGF1 modulators under investigation

Parkinson's Disease

IGF1 provides neuroprotection to dopaminergic neurons
Motor performance improvements in PD models with IGF1 treatment
Interaction with dopamine signaling pathways

ALS

IGF1 promotes motor neuron survival
Delivery challenges due to blood-brain barrier
Gene therapy approaches being explored

Therapeutic Approaches

Research Directions

Current research focuses on:

Understanding tissue-specific IGF1 signaling
Developing brain-penetrant IGF1 analogs
Combination therapies targeting multiple pathways
Biomarkers for IGF1 response monitoring

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Smartphone-Detected Motor Variability Correction](/hypothesis/h-072b2f5d) — 0.63 · Target: DRD2/SNCA
[Microbial Metabolite-Mediated α-Synuclein Disaggregation](/hypothesis/h-74777459) — 0.57 · Target: SNCA, HSPA1A, DNMT1
[Enteric Nervous System Prion-Like Propagation Blockade](/hypothesis/h-2e7eb2ea) — 0.55 · Target: TLR4, SNCA
[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — 0.71 · Target: P2RY12

Related Analyses:

[Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄
[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄

📖 View canonical wiki page →

GBA Gene Therapy for Parkinson's Disease

GBA Gene Therapy for Parkinson's Disease

Introduction

Overview

GBA Gene Therapy for Parkinson's Disease

Introduction

Overview

Background

GBA Mutations and Parkinson's Disease

The GCase-Lysosome Connection

Therapeutic Approaches

1. Enzyme Replacement Therapy (ERT)

2. Gene Therapy Vectors

AAV Vectors

Lentiviral Vectors

3. Small Molecule Chaperones

4. Substrate Reduction Therapy

5. Gene Editing (CRISPR/Cas9)

Clinical Development

Ongoing Trials

Challenges

Mechanism of Action

In Parkinson's Disease

Downstream Effects

Preclinical Evidence

Animal Models

Cell Models

Comparison to Other PD Gene Therapies

Future Directions

Promising Strategies

Key Questions

Related Content

Related Diseases

Related Genes

Related Mechanisms

Related Treatments

Key Publications

See Also

External Links

Allen Brain Atlas Resources

Allen Brain Atlas Resources

References

IGF1 in Neurodegeneration

Alzheimer's Disease

Parkinson's Disease

ALS

Therapeutic Approaches

Research Directions

Related Hypotheses